Evidence map›Paper›PMID 39109368›Full record

ReviewFrontiers in psychiatry2024

Gut microbiota: a potential influencer of insomnia occurring after COVID-19 infection.

Jiale Fang, Siwen Wang, Lijia Liu, Xiaoyi Zhang, Ruilong Liu, Xingchao Pang, Jiankun Cui, Jianshu Han, Xinyu Zhu

Abstract readReview
In one paragraph

Review in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiale FangThe Third Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Siwen WangThe Second Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Lijia LiuThe Third Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Xiaoyi ZhangThe Third Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Ruilong LiuThe Third Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Xingchao PangThe Third Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Jiankun CuiThe First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Jianshu HanThe Third Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Xinyu ZhuThe Third Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of insomnia has increased in recent years, significantly affecting the lives of many individuals. Coronavirus disease 2019 (COVID-19) infection has been found to have a substantial impact on the human gut microbiota (GM). Clinical studies have shown that the high prevalence, prolonged duration, and refractory treatment of insomnia symptoms following the COVID-19 pandemic may be related to the effect of COVID-19 infection on the GM. Therefore, the GM may be a potential target for the treatment of insomnia following COVID-19 infection. However, relevant studies have not been well-documented, and the GM has not been sufficiently analyzed in the context of insomnia treatment. Herein, we review the interaction between sleep and the GM, summarize the characteristics of COVID-19-induced abnormal changes in the GM and metabolites in patients with insomnia, and discuss potential mechanisms, including metabolic, immune, and neural pathways, by which these abnormal changes in the GM cause insomnia as well as the factors affecting the GM. Finally, we discuss the prospect of modulating the host GM community for the effective treatment of insomnia after COVID-19 infection and the need for further clinical studies.

Indexed as

COVID-19gut microbiotainsomniaprobiotic bacteriatraditional Chinese medicine

Identifiers

PMID39109368
PMCPMC11300359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.